Therapie der Hepatitis B und C - Standards 2004

Literatur

• 1 EASL consensus conference panel . Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B.  J Hepatol. 2003;  39 (Suppl 1) S1-235
• 2 Fried M W, Shiffman M L, Reddy K R, Smith C, Marinos G, Goncales F L, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 3 Hadziyannis S J, Sette H, Morgan T R, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros P J, Lin A, Ackrill A M;. PEGASYS International Study Group . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.  Ann Intern Med. 2004;  140 346-355
• 4 Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns M P. Treatment of acute hepatitis C with interferon alfa-2b.  N Engl J Med. 2001;  345 1452-1457
• 5 Janssen H LA, Senturk H, Zeuzem S, Akarca U, Cakaloglu Y, Simon K, So Man Kit T, Gerken G, Schalm S W. for the HBV 99 - 01 Study Group . Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients (Abstract).  Hepatology. 2003;  38 (Suppl 1) 246A
• 6 Keeffe E B, Dieterich D T, Han S H, Jacobson I M, Martin P, Schiff E R, Tobias H, Wright T L. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.  Clin Gastroenterol Hepatol. 2004;  2 87-106
• 7 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000 - summary of a workshop.  Gastroenterology. 2001;  120 1828-1853
• 8 Manns M P, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M, Albrecht J K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
• 9 Marcellin P, Lau G KK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu Z -M, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai M -Y, Button P, Pluck N. A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40kD) (Pegasys) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe positive chronic hepatitis B (Abstract).  Hepatology. 2003;  38 (Suppl 1) 724A
• 10 National Institutes of Health consensus development conference statement . Management of hepatitis C: 2002.  Hepatology. 2002;  36 (Suppl) S3-S15
• 11 Poynard T, Regimbeau C, Myers R P, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski J P. Interferon for acute hepatitis C.  Cochrane Database Syst Rev. 2002;  1 CD000369
• 12 Sarrazin U, Zeuzem S. Therapie der Hepatitis B.  Der Kassenarzt. 2003;  3 32-37
• 13 Sung J JY, Lai J Y, Zeuzem S, Chow W C, Heathcote E, Perrillo R, Brosgart C, Woessner M, Scott S A, Campbell F M. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis (Abstract).  J Hepatol. 2003;  38 (Suppl 2) 25
• 14 Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Farci P, Gitlin N, Lamour F, Lardelli P, Shiffman M. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin (Copegus®) (Abstract).  Hepatology. 2003;  38 (Suppl 1) 208A
• 15 Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?.  Ann Intern Med. 2004;  140 370-381